NVST
Envista Holdings Corp
NVST's fundamentals are strong and it looks cheap: trading at 6.4x earnings, less than half its usual 28x. Analysts expect strong earnings growth.
NVST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Stable | |
| Strong |
NVST's profitability and balance sheet are currently strong, and its revenue and cash flow are stable.
NVST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 6.4x | $24.66 | — |
| Forward | 15x | $24.66 | — |
| Cheap | 21x | $81.70 | +231% |
| Fair | 28x | $108 | +339% |
| Expensive | 95x | $368 | +1394% |
Historical ranges are pointers, not guarantees.
NVST's PE is in its cheap range at 6.4x. On analysts' estimates for next year's earnings, today's price would be 15x.
NVST Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for NVST, with profitability improving.
NVST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.62 | -58% |
| Q3 2026 | $3.87 | +4738% |
| Q2 2026 | $0.58 | +87% |
| Q1 2026 | $0.41 | +$6.95 |
| Q4 2025 | $0.28 | +$6.78 |
| Q3 2025 | $0.08 | +$7.84 |
| Q2 2025 | $0.31 | +$8.00 |
| Q1 2025 | -$6.54 | -$5.83 |
| Q4 2024 | -$6.50 | -$5.90 |
NVST's earnings per share have jumped to their highest in seven years: $3.87 over the past year, up from $0.08 the year before.
NVST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $691.5M | +3.2% |
| Q2 2026 | $730.5M | +7.1% |
| Q1 2026 | $705.5M | +14% |
| Q4 2025 | $750.6M | +15% |
| Q3 2025 | $669.9M | +11% |
| Q2 2025 | $682.1M | +7.7% |
| Q1 2025 | $616.9M | -1.1% |
| Q4 2024 | $652.9M | +1.1% |
NVST's revenue has grown year over year for six quarters in a row: $692M last quarter, up 3.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 75% | +66 points |
| Q2 2026 | 11% | +4.2 points |
| Q1 2026 | 8.9% | +2.5 points |
| Q4 2025 | 9.8% | +2.7 points |
| Q3 2025 | 8.6% | +5.1 points |
| Q2 2025 | 6.8% | +189 points |
| Q1 2025 | 6.3% | -1.4 points |
| Q4 2024 | 7.1% | +39 points |
NVST's operating margin was 75% last quarter, up 66 points from the same quarter a year ago, near the top of its range since 2019.
NVST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $61.8M | -9% |
| Q2 2026 | $104.3M | +37% |
| Q1 2026 | -$15.8M | -$10.2M |
| Q4 2025 | $91.7M | -26% |
| Q3 2025 | $67.9M | +7.3% |
| Q2 2025 | $76.4M | -11% |
| Q1 2025 | -$5.6M | -119% |
| Q4 2024 | $123.8M | +32% |
NVST still generates free cash flow, though less than at its 2020 peak: $242M over the past year.
NVST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -700K shares |
| 1 year | -1.6% | -2.7M shares |
| 3 years | -6.7% | -11.8M shares |
| 5 years | -8.3% | -14.7M shares |
| Available history | +20% | +27M shares |
NVST has 163M diluted shares, down 1.6% from a year ago, with $137M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10M |
| Q2 2026 | $60.3M |
| Q1 2026 | $42.7M |
| Q4 2025 | $24.3M |
| Q3 2025 | $42M |
| Q2 2025 | $85.7M |
| Q1 2025 | $14.6M |
NVST spent $137M buying back its own shares over the past year.
NVST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2024 | 12.5x | High |
| Q4 2023 | 8.5x | High |
NVST's net debt is less than a year of its operating earnings (EBITDA), down from 1.1 years a year ago.
NVST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.8 | Neutral |
| Stochastic | 33.0 | Neutral |
NVST's weekly RSI is 49 (neutral) and its Stochastic is 33 (neutral).
NVST PE vs Healthcare Sector
| Metric | NVST | Sector median | Relative |
|---|---|---|---|
| PE | 6.4x | 26x | 75% below |
| PE % | 0 | 29 | 29 pts below |
NVST is trading at 6.4x earnings, a 75% discount to the Healthcare sector's median of 26x.
NVST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.8 | 3.7% above |
| 20 week MA | $25.5 | 3.4% below |
| 50 week MA | $25.2 | 2.2% below |
| 100 week MA | $22.3 | 11% above |
| 200 week MA | $24.1 | 2.3% above |
NVST's trend is mixed: it's above three of its five weekly moving averages, and 2.3% above its 200-week average.
NVST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.0 | $32.4 | +8.1% |
| 2021 | $32.4 | $45.7 | +41% |
| 2022 | $45.7 | $33.1 | -28% |
| 2023 | $33.1 | $24.1 | -27% |
| 2024 | $24.1 | $19.2 | -20% |
| 2025 | $19.2 | $22.0 | +14% |
| 2026 YTD | $22.0 | $24.7 | +12% |
NVST has finished lower in three of the last six years. It's up 12% so far in 2026.